tiprankstipranks
Trending News
More News >
Eagle Pharmaceuticals Inc (EGRX)
OTHER OTC:EGRX
US Market

Eagle Pharmaceuticals (EGRX) Income Statement

Compare
212 Followers

Eagle Pharmaceuticals Income Statement

Last quarter (Q2 2023), Eagle Pharmaceuticals's total revenue was $64.65M, a decrease of -12.80% from the same quarter last year. In Q2, Eagle Pharmaceuticals's net income was $5.16M. See Eagle Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 316.61M$ 171.55M$ 187.80M$ 195.89M$ 213.31M
Gross Profit
$ 221.67M$ 129.37M$ 142.34M$ 135.00M$ 151.40M
Operating Expenses
$ 140.71M$ 126.60M$ 109.38M$ 113.18M$ 104.93M
Depreciation and Amortization
$ 12.02M$ 3.76M$ 4.77M$ 4.65M$ 3.67M
EBITDA
$ 77.50M$ 847.00K$ 30.02M$ 29.34M$ 40.44M
Operating Income
$ 80.96M$ 2.77M$ 32.95M$ 21.82M$ 36.62M
Other Income/Expenses
$ -19.53M$ -7.32M$ -10.28M$ 183.00K$ -2.58M
Pretax Income
$ 61.43M$ -4.55M$ 22.68M$ 22.00M$ 34.04M
Net Income
$ 35.64M$ -8.63M$ 11.99M$ 14.31M$ 31.90M
Per Share Metrics
Basic EPS
$ 2.76$ -0.66$ 0.89$ 1.04$ 2.16
Diluted EPS
$ 2.73$ -0.66$ 0.87$ 1.01$ 2.09
Weighted Average Shares Outstanding
12.93M 13.05M 13.48M 13.75M 14.77M
Weighted Average Shares Outstanding (Diluted)
13.07M 13.05M 13.77M 14.14M 15.28M
Currency in USD

Eagle Pharmaceuticals Earnings and Revenue History